Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Other Non-Current Assets (2022 - 2025)

Entrada Therapeutics has reported Other Non-Current Assets over the past 4 years, most recently at $70000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $70000.0 for Q4 2025, down 98.23% from a year ago — trailing twelve months through Dec 2025 was $70000.0 (down 98.23% YoY), and the annual figure for FY2025 was $70000.0, down 98.23%.
  • Other Non-Current Assets for Q4 2025 was $70000.0 at Entrada Therapeutics, down from $4.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for TRDA hit a ceiling of $13.8 million in Q1 2023 and a floor of $70000.0 in Q4 2025.
  • Median Other Non-Current Assets over the past 4 years was $4.0 million (2022), compared with a mean of $3.6 million.
  • Biggest five-year swings in Other Non-Current Assets: surged 634.2% in 2024 and later crashed 98.23% in 2025.
  • Entrada Therapeutics' Other Non-Current Assets stood at $5.2 million in 2022, then decreased by 24.18% to $4.0 million in 2023, then changed by 0.0% to $4.0 million in 2024, then crashed by 98.23% to $70000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $70000.0 (Q4 2025), $4.0 million (Q3 2025), and $199000.0 (Q2 2025) per Business Quant data.